Contact Transscleral Diode Laser Cyclophotocoagulation For Treatment Of Refractory Glaucoma

Objective: To evaluate the short-term outcome of contact transscleral diode laser cyclophotocoagulation(CTDC) for treatment of refractory glaucoma. Methods: We collected the patients of refractory glaucoma from 2000.1 to 2007.2 in the First Affiliated Hospital of Xinjiang Medical University: 30 cases(30 eyes) treated by CTDC, and 30 cases(30 eyes) treated by cyclocryotherapy. The laser parameters of CDTC: 1 050～2 800 mW power, 1 000～2 000 ms exposure, and 7～28 shots in 180°- 360°range. To follow up and document preoperative IOP and postoperative IOPs on 3 days, and at weeks 1,2,3 and 1 month, respectively and symptoms, complications and medications. Efficiency was defined as an intraocular pressure less than or equal to 21 mm Hg or absence of pain for poorly sighted and blind eyes. Follow-up observations were made for all patients for 1 month. Result: There were significant difference between preoperative and postoperative IOP in the two groups (P<0.001). In comparison with cyclocryotherapy, there were significant difference of postoperative IOP on 3 days, and at 1 week and 1 month, respectively(P<0.05). There were significant difference between preoperative and all postoperative time of IOP in the two groups respectively(P<0.001). The operating efficiency of CTDC group was 93.33%, and of cyclocryotherapy group was 83.33%. Pain relief rate of CTDC grouop was 96.67%, and of cyclocryotherapy group was 86.67%. there were no severe complications postoperatively in both groups.Conclusions: CTDC is a safe and effective therapy for the eyes with refractory glaucoma.